Shares of Revelation Biosciences, Inc. (NASDAQ:REVB – Free Report) are going to reverse split on the morning of Tuesday, October 20th. The 1-7 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, October 19th.
Revelation Biosciences Stock Performance
REVB stock traded down $0.28 during midday trading on Friday, hitting $0.48. 632,488 shares of the company’s stock were exchanged, compared to its average volume of 240,393. The company has a market cap of $1.93 million, a PE ratio of -0.04 and a beta of -0.07. The stock’s fifty day moving average price is $0.95 and its 200-day moving average price is $1.03. Revelation Biosciences has a one year low of $0.47 and a one year high of $5.80.
Revelation Biosciences (NASDAQ:REVB – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.87) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.01. On average, analysts expect that Revelation Biosciences will post -5.18 EPS for the current year.
Analysts Set New Price Targets
Separately, Weiss Ratings cut Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a research note on Wednesday. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.
Get Our Latest Stock Analysis on REVB
About Revelation Biosciences
Revelation Biosciences, Inc is a clinical-stage biotechnology company focused on developing therapies that activate and regulate the body’s innate immune system. Its research is aimed primarily at addressing infectious diseases and inflammatory conditions, particularly those affecting the respiratory system.
The company’s pipeline includes intranasal product candidates designed to stimulate localized immune responses in the nose and airways. Its lead candidate, REVTx-99, has been developed as an investigational therapy for respiratory conditions, including the prevention or reduction of complications associated with severe respiratory infections.
See Also
- Five stocks we like better than Revelation Biosciences
- Bank of America Stock Sell-Off Looks Like a Buying Opportunity
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Receive News & Ratings for Revelation Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revelation Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
